PD-L1 as a response biomarker to chemotherapy plus immune checkpoint inhibitors in operable gastroesophageal adenocarcinoma: a meta-analysis of neoadjuvant clinical trials
Perioperative ChT-ICI improves pathological response rates in operable GEA and PD-L1 ≥5 is a significant biomarker of pCR, supporting stratification by PD-L1 and the design of biomarker-selected trials.
Authors
- Antonella Cammarota (ORCID: https://orcid.org/0000-0001-9967-4694)
- Sheraz R. Markar (ORCID: https://orcid.org/0000-0001-8650-2017)
- Sivesh Kathir Kamarajah (ORCID: https://orcid.org/0000-0002-2748-0011)
- Elizabeth Smyth
Institutions
- Humanitas University (IT)
- Sarah Cannon Research Institute (GB)
- Churchill Hospital (GB)
- University of Oxford (GB)
- Centre for Global Health Research (CA)
Publication Details
- Journal
- ESMO Gastrointestinal Oncology
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1016/j.esmogo.2024.100107
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- NIHR Oxford Biomedical Research Centre